Freestone Grove Partners’s Tandem Diabetes Care TNDM Stock Holding History

Freestone Grove Partners’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.2M	Buy	1,866,134 +535,392	+40%	+$9.35M	0.18%	165
2026 Q1	$25.5M	Sell	1,330,742 -112,094	-8%	-$2.44M	0.18%	182
2025 Q4	$31.7M	Sell	1,442,836 -427,471	-23%	-$7.71M	0.23%	146
2025 Q3	$22.7M	Buy	+1,870,307	New	+$25.3M	0.17%	185
2025 Q1	–	Sell	-181,124	Closed	-$6.52M	–	788
2024 Q4	$6.52M	Buy	+181,124	New	+$6.13M	0.08%	222

Other funds holding TNDM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Freestone Grove Partners's TNDM Position: Q2 2026 in Review

Freestone Grove Partners increased its Tandem Diabetes Care (TNDM) stake by 40% in Q2 2026, buying an estimated $9.35M and bringing the position to 1,866,134 shares worth $28.2M. The position accounts for 0.18% of the portfolio, ranked #165.

Freestone Grove Partners first reported a position in TNDM in Q4 2024 and has held it in 5 quarters since. The position peaked at $31.7M in Q4 2025. 273 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

Freestone Grove Partners held 1,866,134 shares of Tandem Diabetes Care worth $28.2M as of Q2 2026.
Freestone Grove Partners bought 535,392 Tandem Diabetes Care shares in Q2 2026, an estimated $9.35M.
Tandem Diabetes Care made up 0.18% of Freestone Grove Partners's portfolio in Q2 2026, its #165 holding.
Freestone Grove Partners first reported a position in Tandem Diabetes Care in Q4 2024 and has held it in 5 quarters since.
Freestone Grove Partners's Tandem Diabetes Care position peaked at $31.7M in Q4 2025.
273 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.